Test results for new cancer drug take Akeso investors on wild ride
Shares in the Chinese pharmaceutical company swung back and forth as investors tried to make sense of clinical trial data for an immunotherapy drug billed as a potential world beater…
Recent Articles
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
